The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study
Yanan Liu,Shuo Zhang,Rongrong Hu,Chao Li,Gang Chen,Xiaoxiao Shi,Yan Liu,Ke Zheng,Hang Li,Yubing Wen,Xuemei Li,Xuewang Li,Peng Xia,Yan Qin
DOI: https://doi.org/10.2147/IJGM.S410169
IF: 2.145
2023-05-24
International Journal of General Medicine
Abstract:Yanan Liu, Shuo Zhang, Rongrong Hu, Chao Li, Gang Chen, Xiaoxiao Shi, Yan Liu, Ke Zheng, Hang Li, Yubing Wen, Xuemei Li, Xuewang Li, Peng Xia, Yan Qin Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China Correspondence: Peng Xia; Yan Qin, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, People's Republic of China, Tel +86 01069155058, Email ; Purpose: There are increasing reports of atypical membranous nephropathy (AMN) cases with similar pathological characteristics to secondary membranous nephropathy (SMN) without definite underlying causes. Although rituximab has become a first-line option in treating idiopathic membranous nephropathy (IMN), the efficacy and safety of rituximab-based regimen for AMN is not clear. Patients and Methods: This is a retrospective, single-center study. AMN patients who received rituximab-based therapy were included. IMN patients treated with rituximab during the same period were selected as the control group matched by gender, sex, baseline urinary protein and albumin levels. Baseline data and follow-up data were collected. Results: A total of 20 AMN patients and 40 IMN patients were included. The baseline levels of urinary protein were comparable between the two groups [6.77 (IQR 3.34, 11.49) g/24 h vs 6.47 (IQR 3.4, 10.76) g/24 h, P=0.944]. The baseline levels of serum albumin were 26.15± 6.71 g/L and 26.8± 5.54 g/L (P=0.689) respectively. The cumulative remission rate for rituximab-based treatment at the 12th month was lower in AMN group than IMN group [13 (65%) vs 36 (90%), P=0.045]. In AMN group, non-responders showed a higher level of proteinuria and a worse renal function at baseline than those of responders. There was no significant difference in the overall adverse events or serious adverse events between the two groups. Conclusion: In our study, AMN patients obtained proteinuria remission in a lower percentage compared with IMN patients. In general, rituximab-based therapy is effective in AMN patients with an acceptable safety profile. Keywords: rituximab, atypical membranous nephropathy, idiopathic membranous nephropathy, efficacy Membranous nephropathy (MN) is a leading cause of nephrotic syndrome (NS) in adults. 1 Approximately one-third of MN cases are classified as secondary MN (SMN) because they could be attributed to systemic autoimmune diseases, infections, malignancies, or medications. 2 According to immunofluorescence (IF), light microscopy (LM), and electron microscopy (EM), SMN has its own unique pathological characteristics, including positive C1q deposition, mesangial and endothelial cell proliferation, and deposits of subendothelial and subepithelial electron dense materials. 3 In recent years, there have been increasing reports of atypical MN (AMN) cases. 4–6 This group of patients usually showed similarity of pathological characteristics to SMN but no definite underlying causes of MN could be identified. According to a Chinese single-center study, 5 the main clinical manifestation in patients with AMN is nephrotic syndrome and hematuria is more common compared with idiopathic MN (IMN). Based on recent data, serum PLA2R antibody could not be used to differentiate AMN from IMN. 5 There is no uniform treatment regimen for AMN patients with nephrotic syndrome. The most widely used immunosuppressive therapies (IST) included corticosteroids combined with alkylating agents and calcineurin inhibitors (CNIs) based regimen. It seemed that the renal outcomes were similar between IMN and AMN patients. 6 Nonetheless, adverse effects such as severe infections and metabolic abnormalities still remained a matter of concern. 7,8 In the past decade, rituximab has emerged as a promising new first-line therapeutic option with positive results in the treatment of IMN. 9–14 The efficacy and safety of a rituximab-based regimen for nephrotic syndrome brought on by AMN, however, have not been described. In this study, we reported 20 AMN patients treated with Rituximab-based regimen. Comparisons were made between AMN and IMN patients in treatment response and side effects. This is a single-center, retrospective study conducted in Peking Union Medical College Hospital (PUMCH). All IMN and AMN patients admitted to the Department of Nephrology from January 2017 to January 2022 were screened. The inclusion criteria for the AMN patients were as follows: 1) in addition to immune complex deposition under the epithelial and thickening GBM, renal biopsy showed at least one of the following character -Abstract Truncated-
medicine, general & internal